# US Human Vaccines Market

> US Human Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Applications (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal) and By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.61%
- **2024:** $ 151.52 Million
- **2025:** $ 160.02 Million
- **2035:** $ 276.25 Million
- **Key Players:** Pfizer (US), Moderna (US), AstraZeneca (GB), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), Novavax (US), Bharat Biotech (IN)

**Report ID:** MRFR/Pharma/14106-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-human-vaccines-market-15633

---

## Market Summary

## **US Human Vaccines Market Overview**

As per MRFR analysis, the US Human Vaccines Market Size was estimated at 9.72 (USD Billion) in 2023. The US Human Vaccines Market Industry is expected to grow from 10.5(USD Billion) in 2024 to 17 (USD Billion) by 2035. The US Human Vaccines Market CAGR (growth rate) is expected to be around 4.478% during the forecast period (2025 - 2035).

### **Key US Human Vaccines Market Trends Highlighted**

The US Human Vaccines Market is experiencing significant growth driven by several key factors. One of the primary drivers is the increasing prevalence of infectious diseases and the recognition of vaccines as a vital public health tool. The recent COVID-19 pandemic underscored the importance of rapid vaccine development and distribution, prompting enhanced government funding and support for vaccine research and manufacturing capabilities. Additionally, the growing awareness of vaccine benefits among the population has led to increased immunization rates, contributing to overall market expansion.

Opportunities in the US market are rapidly evolving, particularly with the advent of mRNA technology and advancements in personalized medicine. Companies are exploring these innovations to create vaccines for not just infectious diseases but also for conditions like cancer. The increased focus on preventative healthcare further opens doors for vaccine development, highlighting the potential for a wider range of immunizations to enhance population health outcomes.

Recent trends in the US Human Vaccines Market include a shift towards broader vaccine acceptance, driven by educational campaigns and endorsements from health authorities. The government supports immunization programs, with initiatives like the Vaccines for Children program offering vaccines at no cost to eligible children, which helps diminish barriers to access. Moreover, the integration of digital health technologies into the vaccination process is becoming more prevalent, enabling easier tracking and management of vaccination records. The push for routine vaccinations in adults has gained traction, amplifying the demand for more comprehensive vaccine schedules.

Overall, the combination of increased awareness, technological advancements, and government support continues to shape the US Human Vaccines Market significantly.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Human Vaccines Market Drivers**

### **Increased Government Funding and Support for Vaccination Programs**

The US Human Vaccines Market Industry has been significantly bolstered by increased government funding and support for vaccination initiatives. The Centers for Disease Control and Prevention (CDC) reported that the federal budget for vaccination programs has reached over 4 billion USD annually, especially following the COVID-19 pandemic response, which has prioritized vaccine distribution and development. This surge in funding facilitates Research and Development efforts aimed at creating new vaccines and improving existing ones, thus driving market growth.

The National Institutes of Health (NIH) also actively invests in various vaccine-related projects, which has advanced immunization protocols and promoted public trust in vaccines. With rising healthcare demands in the US, this financial backing is expected to continue, promising a brighter future for the industry as innovative vaccine solutions become more accessible.

### **Growing Public Awareness about Preventable Diseases**

There is an increasing public awareness regarding the impact of preventable diseases, which is significantly impacting the US Human Vaccines Market Industry. The CDC has highlighted that vaccination rates against diseases such as measles and influenza have become critical in maintaining public health safety and reducing outbreaks. Recent statistics show that there was a 15% increase in flu vaccine coverage in the US healthcare population last season, as more individuals recognize the importance of immunizations.

This growing awareness is also fueled by advocacy groups like the Immunization Action Coalition, which work to educate the public about the benefits of vaccination, thereby promoting acceptance. This trend contributes to a sustained demand for vaccines and supports the market's expansion.

### **Rising Incidence of Infectious Diseases**

The rising incidence of infectious diseases in the United States is a critical driver for the growth of the US Human Vaccines Market Industry. According to reports from the CDC, infectious diseases such as pertussis and COVID-19 have seen resurgence, indicating a need for enhanced immunization efforts. For instance, the CDC reported that the number of pertussis cases increased by 20% from the previous year, underlining the necessity for effective vaccines to combat these diseases.

These alarming trends have prompted both government and private sector initiatives geared towards developing new vaccines. With organizations like the World Health Organization (WHO) emphasizing vaccination as a primary preventive measure, the increasing prevalence of infectious diseases will likely lead to greater investments in vaccine R&D, thus driving market growth.

## **US Human Vaccines Market Segment Insights**

### **Human Vaccines Market Vaccine Type Insights**

The Vaccine Type segment of the US Human Vaccines Market plays a crucial role in infection control and public health by offering various methodologies to combat diseases. This segment includes diverse categories of vaccines such as Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines, each with unique characteristics, applications, and market demand. Inactivated vaccines, which are derived from killed pathogens, are widely utilized for their stability and safety profile, making them essential in ensuring broad immunization coverage in the population.

On the other hand, Live Attenuated vaccines possess the advantage of eliciting a robust immune response due to their resemblance to actual infections, providing long-lasting immunity which is indispensable for managing endemic diseases. Additionally, Subunit vaccines have gained prominence for their ability to utilize specific elements of pathogens, minimizing side effects while maintaining efficacy, thus appealing to both healthcare providers and patients. Recombinant vaccines represent a significant advancement in technology, enabling the production of vaccines that are both effective and tailored, further driving innovations in vaccine development.

Toxoid vaccines, which neutralize toxins produced by bacteria, are vital in preventing diseases such as tetanus and diphtheria, underscoring their importance in the broader vaccination landscape. The US Human Vaccines Market emphasizes the significance of these various types, considering factors such as market growth, public health initiatives, and demographic needs. As healthcare policies evolve in response to global health challenges, the strategic distribution and administration of these vaccines will remain essential to maintaining population immunity and eradicating serious infectious diseases.

Moreover, the burgeoning emphasis on Research and Development and government support play an influential role in shaping the dynamics and advancements within this segment, ultimately reflecting the broader trends in healthcare in the United States. With increasing awareness and acceptance of vaccinations driven by educational campaigns and scientific evidence, the market for these vaccine types is expected to reflect positive growth trajectories, showcasing their integral role in the continuum of healthcare and disease prevention in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Human Vaccines Market Application Insights**

The US Human Vaccines Market, particularly within the Application segment, plays a crucial role in public health and disease prevention. Preventive Vaccines, designed to avert diseases before they occur, represent a significant portion of the market as they effectively reduce the incidence of various infectious diseases, thus supporting community immunity. Therapeutic Vaccines are emerging as vital for treating existing diseases and are gaining traction in fields like oncology, reflecting a shift towards personalized medicine.

Travel Vaccines, aiming to protect individuals from diseases prevalent in specific regions, showcase the growing importance of global travel and the need for proactive health measures in a connected world. Influenza Vaccines remain pivotal during seasonal outbreaks, underscoring the necessity for annual immunization to minimize public health risks. Overall, these diverse applications underscore the dynamic nature of the market and highlight essential growth drivers such as increased awareness, ongoing Research and Development efforts, and the rising incidence of infectious diseases, all contributing to a robust framework for the US Human Vaccines Market revenue generation.

### **Human Vaccines Market Administration Route Insights**

The Administration Route segment of the US Human Vaccines Market plays a critical role in the effective delivery of vaccines to the population, ensuring efficient immunization against various diseases. This segment encompasses multiple methods such as Intramuscular, Subcutaneous, Oral, and Intradermal routes, each with its own set of advantages and suitable applications. Intramuscular administration remains a dominant choice due to its efficacy in delivering vaccines, particularly for those requiring deeper tissue entry for optimal immune response.

Subcutaneous administration offers ease of use and patient comfort, making it favorable in certain vaccination scenarios. The Oral route is increasingly appreciated for its non-invasive nature, allowing for easier administration, especially in pediatric and mass immunization campaigns. Intradermal delivery is gaining traction, particularly for specific vaccines, due to its potential for reduced dosage while maintaining immunogenicity. Overall, the Administration Route segment is essential for driving market growth and ensuring that vaccination efforts are both accessible and effective, addressing the healthcare needs of the US population through a range of delivery methods tailored to various situations and demographics.

Factors such as advancements in vaccine technology, public health initiatives, and increasing awareness of vaccination benefits further contribute to the expansion of this market segment.

### **Human Vaccines Market Target Diseases Insights**

The US [Human Vaccines](../../../reports/human-vaccines-market-2671) Market, focusing on Target Diseases, encompasses a variety of critical health threats that necessitate vaccination strategies. Infectious diseases remain a predominant concern, with illnesses such as influenza, COVID-19, and various childhood vaccinations significantly driving market demand. Vaccination for oncological diseases is gaining traction as advancements in immunotherapy are opening new avenues to prevent and treat cancers, leading to increased investments in Research and Development.

Autoimmune diseases present a unique challenge, with a growing understanding of their underlying mechanisms prompting increased focus on developing targeted vaccinations. Each of these areas presents substantial opportunities for growth, influenced by rising healthcare costs and a heightened emphasis on preventive care. Collaborative efforts among healthcare providers and governments are vital, with statistics showing vaccine efficacy can significantly reduce the burden of these diseases. Overall, the Target Diseases segment plays an essential role in shaping public health strategies and improving population health outcomes across the US.

## **US Human Vaccines Market Key Players and Competitive Insights**

The competitive landscape of the US Human Vaccines Market is characterized by a dynamic interplay of established pharmaceutical giants and innovative biotech firms. The market is driven by increasing public awareness of vaccine developments, government initiatives to improve vaccination rates, and the growing prevalence of infectious diseases. Amidst the backdrop of the COVID-19 pandemic, the importance of effective vaccines has gained unprecedented recognition, leading to heightened competition and significant investment in vaccine research and development. Companies are now focusing on expanding their product portfolios, leveraging advanced technologies, and forming strategic partnerships to enhance their market positions.

As a result, the competitive insights reveal a landscape marked by innovation, rigorous regulatory scrutiny, and a commitment to public health, with companies striving to address the evolving needs of patients and healthcare systems.

Merck and Co holds a prominent position in the US Human Vaccines Market, supported by its comprehensive pipeline of vaccines that cater to various infectious diseases. With a rich history of vaccine development, the company's strengths lie in its strong brand reputation, extensive research capabilities, and established distribution networks. Merck is known for its flagship vaccines, which have consistently demonstrated efficacy and safety, earning the trust of both healthcare providers and the public.

The company continues to invest significantly in R&D activities to introduce next-generation vaccines, and its ability to rapidly respond to emerging health threats positions it as a leader in the field. Furthermore, Merck's strategic collaborations with academic institutions and government agencies enhance its capabilities to innovate and stay ahead of competitors in this ever-evolving market.

Vaxart is an emerging player in the US Human Vaccines Market, focused on developing oral vaccines that offer unique advantages over traditional injectable options. The company's proprietary technology platform allows for the design of vaccines that are stable at room temperature, addressing logistical challenges associated with cold-chain storage. Key products under development include oral vaccines for respiratory viruses, which have shown promise in preclinical studies.

Vaxart's strengths lie in its innovative approach to vaccine delivery, potentially improving vaccine acceptance and adherence among populations. The company's presence in the market is reinforced by strategic partnerships aimed at enhancing its research and development capabilities. Additionally, Vaxart's commitment to advancing its vaccine candidates through clinical trials reflects its ambition to contribute to the broader vaccination landscape in the US. The company’s recent collaborations and potential mergers indicate its strategy to leverage synergies that can further its market position as it navigates the complex regulatory environment of vaccine approval and distribution.

### **Key Companies in the US Human Vaccines Market Include**

## **US Human Vaccines Market Industry Developments**

As of recent months, the US Human Vaccines Market has witnessed significant developments, particularly in response to ongoing global health challenges. In October 2023, Pfizer and Moderna reported increased production capabilities for their mRNA vaccines, focused on addressing proposed booster shots for emerging variants. Merck and Co has intensified its Research and Development efforts in vaccine therapeutics, focusing on collaborations with biotech firms to expedite vaccine innovation. AstraZeneca's vaccine collaboration with various health entities has led to expanding distribution networks in underserved populations across the United States.

In terms of mergers and acquisitions, in August 2023, Novavax completed its acquisition of a biotechnological firm specializing in vaccine delivery systems to enhance its product pipeline. There have also been reports of increased valuations for companies such as GlaxoSmithKline and Johnson and Johnson, fueled by enhanced funding for vaccine accessibility and newer product developments aimed at combating infectious diseases. The market growth has been positively impacted by regulatory support from US health agencies, stimulating demand for diverse vaccine options, as the country remains vigilant against potential influenza surges and new viral threats.

Overall, these activities signify a dynamic phase in the US Human Vaccines Market.

## **US Human Vaccines Market Segmentation Insights**

### **Human Vaccines Market Vaccine Type Outlook**

### **Human Vaccines Market Application Outlook**

### **Human Vaccines Market Administration Route Outlook**

### **Human Vaccines Market Target Diseases Outlook**

## Market Drivers

### Rising Public Health Awareness

Rising public health awareness is a key driver of the human vaccines market. Educational campaigns and community outreach programs have significantly increased knowledge about the benefits of vaccination. The CDC and various health organizations have been actively promoting vaccination as a critical tool for disease prevention. Surveys indicate that public confidence in vaccines has improved, with over 80% of adults recognizing the importance of immunization. This heightened awareness is likely to translate into higher vaccination rates, thereby expanding the human vaccines market. As of 2025, the market is projected to grow by 5% annually, driven by this increasing public engagement and understanding of vaccine efficacy.

### Advancements in Vaccine Technology

Advancements in vaccine technology are significantly influencing the human vaccines market. Innovations such as mRNA technology and viral vector platforms have revolutionized vaccine development, allowing for faster and more effective responses to emerging infectious diseases. The introduction of mRNA vaccines has demonstrated a remarkable efficacy rate of over 90% in clinical trials, which has encouraged further investment in research and development. As of 2025, market is projected to reach $40 billion, with a notable increase in the number of vaccines entering the pipeline.. These technological advancements not only enhance vaccine efficacy but also improve safety profiles, thereby fostering public trust and acceptance of vaccinations.

### Government Initiatives and Funding

Government initiatives play a crucial role in shaping the human vaccines market. The US government has allocated substantial funding for vaccine research and development, particularly in response to emerging health threats. For instance, the National Institutes of Health (NIH) and the CDC have launched programs aimed at accelerating vaccine innovation. In 2024, federal funding for vaccine programs reached $5 billion, reflecting a commitment to enhancing public health infrastructure. These initiatives not only support the development of new vaccines but also facilitate access to existing vaccines, thereby increasing overall vaccination rates. As a result, the human vaccines market is likely to expand, driven by these supportive policies and funding mechanisms.

### Rising Incidence of Infectious Diseases

human vaccines market is experiencing growth due to rising incidence of infectious diseases in the US.. Reports indicate that vaccine-preventable diseases, such as measles and pertussis, have seen a resurgence, prompting public health initiatives to increase vaccination rates. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of vaccination in controlling outbreaks, which has led to increased funding for vaccine development and distribution. In 2023, the market was valued at approximately $30 billion, with projections suggesting a compound annual growth rate (CAGR) of 6% through 2030. This trend indicates a robust demand for vaccines, as healthcare providers and policymakers prioritize immunization to safeguard public health.

### Increased Focus on Preventive Healthcare

human vaccines market is benefiting from increased focus on preventive healthcare in the US.. As healthcare systems shift towards value-based care, there is a growing recognition of the importance of vaccination in preventing diseases and reducing healthcare costs. Preventive measures, including vaccinations, are seen as essential components of public health strategies. In 2025, it is estimated that preventive healthcare spending will account for approximately 15% of total healthcare expenditures, highlighting the financial incentives for vaccination programs. This shift in focus is likely to drive demand for vaccines, as both healthcare providers and patients prioritize preventive measures to enhance overall health outcomes.

## Future Outlook

[Human Vaccines Market](https://www.marketresearchfuture.com/reports/human-vaccines-market-2671) projected to grow at a 5.61% CAGR from 2025 to 2035., driven by technological advancements, increasing healthcare investments, and rising disease awareness.

**New opportunities:**

- Development of personalized vaccine solutions for high-risk populations.
- 
- Expansion of telehealth services for vaccine consultations and follow-ups.
- Investment in automated vaccine storage and distribution systems.

By 2035, the human vaccines market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Inactivated (Largest) vs. Live Attenuated (Fastest-Growing)

In the US [human vaccines market](https://www.marketresearchfuture.com/reports/human-vaccines-market-2671), the market share distribution among different types of vaccines reveals that inactivated vaccines hold the largest portion, favored for their effectiveness and safety profile. Live attenuated vaccines, while not the largest, are experiencing rapid growth due to increasing demand for more robust immune responses and the ability to provide long-lasting protection. Other types, such as subunit, recombinant, and toxoid vaccines, although important, occupy smaller market shares in comparison. Growth trends indicate a significant advance in live attenuated vaccines as new technologies enhance their safety and efficacy. Factors behind this emergence include increased public awareness, favorable governmental policies supporting vaccination programs, and ongoing research and development activities. The continuing evolution of health threats further propels the demand for innovative vaccine solutions, driving overall market growth.

Inactivated (Dominant) vs. Live Attenuated (Emerging)

Inactivated vaccines are characterized by their non-replicating pathogens, making them safer for a broader range of populations, including the immunocompromised. This dominance is supported by widespread use in various immunization schedules, enhancing public trust and compliance. Conversely, live attenuated vaccines are emerging as a preferred choice in specific scenarios, particularly where stronger immune responses are vital. They utilize weakened forms of the pathogen, leading to strong and lasting immunity, which is becoming increasingly relevant in the current landscape of rapid virus mutations. Both types are critical in ensuring healthcare systems effectively manage infectious disease outbreaks and maintain population health.

### By Application: Preventive Vaccines (Largest) vs. Therapeutic Vaccines (Fastest-Growing)

The US human vaccines market is characterized by a diverse range of applications, with preventive vaccines holding the largest share. This segment is widely recognized for immunizing against various diseases, thus contributing significantly to public health. Following closely are therapeutic vaccines, which, despite their smaller market share, exhibit rapid growth due to increasing investments in chronic disease management and cancer treatment. In recent years, the growth of preventive vaccines has been driven by heightened awareness of vaccination benefits and government initiatives promoting immunization programs. Conversely, the therapeutic vaccine segment is emerging as the fastest-growing due to advancements in technology and research, addressing unmet medical needs, such as cancer and other chronic conditions, thus attracting substantial funding and interest from major pharmaceutical companies.

Preventive Vaccines: Dominant vs. Therapeutic Vaccines: Emerging

Preventive vaccines remain dominant within the US human vaccines market, primarily focusing on immunization against infectious diseases such as measles, mumps, rubella, and influenza. They not only safeguard individual health but also contribute to herd immunity, thereby ensuring public safety. Conversely, therapeutic vaccines are considered emerging solutions with the potential to treat diseases rather than prevent them. These vaccines target existing conditions, particularly in oncology and chronic illness areas, revealing significant promise but facing challenges related to clinical efficacy and acceptance in the medical community.

### By Administration Route: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

In the US human vaccines market, the administration route segment is predominantly led by intramuscular injections, which occupy the largest share due to their widespread acceptance and efficacy. Subcutaneous injections are also significant and are gaining ground, appealing to patients for their ease of administration. Oral and intradermal routes are less commonly used but serve specific niches in the vaccination landscape. Growth trends indicate that subcutaneous vaccinations are becoming increasingly popular as new formulations and technologies enhance their reliability and patient comfort. Additionally, innovations aimed at reducing needle use and improving patient experience are driving interest in these alternative administration routes. Overall, the ongoing research and development efforts are expected to positively influence the dynamics of this segment in the coming years.

Intramuscular (Dominant) vs. Oral (Emerging)

Intramuscular injections are the dominant method for vaccine administration, favored for their ability to deliver vaccines quickly into the bloodstream, ensuring effective immune response. They are particularly utilized for a range of vaccines, from routine immunizations to emergency responses. On the other hand, oral vaccines represent an emerging area, appreciated for their ease of use and comfort, especially in pediatric populations. However, their development faces challenges such as stability and formulation issues, limiting their uptake relative to intramuscular options. As research progresses, oral vaccines could potentially redefine administration preferences if they address these hurdles effectively.

### By Target Diseases: Infectious Diseases (Largest) vs. Oncological Diseases (Fastest-Growing)

In the US human vaccines market, the market share distribution is predominantly led by the infectious diseases segment, which holds the largest share due to widespread vaccination programs targeting various pathogens. This segment benefits from established networks and strong public health initiatives, resulting in high vaccination rates for diseases such as influenza, HPV, and measles. Meanwhile, the oncological diseases segment is emerging as the fastest-growing area of the market. This growth is driven by the increasing prevalence of cancer and advancements in vaccine technology. As research progresses and more oncology vaccines become available, this segment is expected to see significant expansion in adoption and market presence, reflecting a shift in focus toward preventative measures in cancer care.

Infectious Diseases (Dominant) vs. Oncological Diseases (Emerging)

Infectious diseases vaccines remain the dominant force in the US human vaccines market, characterized by a robust infrastructure and established public trust in vaccination programs. This segment encompasses vaccines for common and severe infections, playing a critical role in maintaining population health. Conversely, oncological diseases vaccines represent an emerging segment, focusing on a new frontier in preventive healthcare. The development of vaccines targeting specific types of cancer fuels growth in this area as more individuals and healthcare providers recognize the importance of preventative strategies. Both segments cater to distinct yet vital needs within the healthcare landscape, with infectious diseases taking precedence while oncological vaccines gain momentum.

## Competitive Benchmarking

The human vaccines market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing emerging health challenges. Key players such as Pfizer (US), Moderna (US), and Johnson & Johnson (US) are at the forefront, leveraging their extensive research capabilities and established market presence. Pfizer (US) has positioned itself as a leader in mRNA technology, while Moderna (US) continues to expand its portfolio beyond COVID-19 vaccines, focusing on personalized medicine and infectious diseases. Johnson & Johnson (US) emphasizes its single-dose vaccine approach, aiming to enhance accessibility and convenience, which collectively shapes a competitive environment that prioritizes rapid response to public health needs.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce lead times. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. This fragmentation allows for diverse approaches to vaccine development and distribution, fostering competition that is not solely based on pricing but also on innovation and operational efficiency.
In October Pfizer (US) announced a strategic partnership with a leading biotechnology firm to co-develop a next-generation vaccine targeting multiple viral strains. This collaboration is expected to enhance Pfizer's capabilities in rapid vaccine development, potentially positioning the company to respond more effectively to future pandemics. The strategic importance of this partnership lies in its potential to streamline the vaccine development process and expand Pfizer's market share in the evolving landscape of infectious disease management.
In September Moderna (US) launched a new initiative aimed at integrating artificial intelligence (AI) into its vaccine research and development processes. This move is likely to accelerate the identification of vaccine candidates and optimize clinical trial designs, thereby enhancing the company's competitive edge. The integration of AI signifies a broader trend within the industry, where technology is increasingly leveraged to improve efficiency and outcomes in vaccine development.
In August Johnson & Johnson (US) expanded its manufacturing capabilities in the US by investing $200 million in a new facility dedicated to vaccine production. This investment underscores the company's commitment to ensuring a robust supply chain and meeting future demand for vaccines. The strategic importance of this expansion is multifaceted, as it not only enhances production capacity but also reinforces Johnson & Johnson's position as a reliable supplier in the market.
As of November current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of advanced technologies such as AI in vaccine development. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to tackle complex health challenges. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will be better positioned to thrive in the future.

## Recent News & Developments

As of recent months, the US Human Vaccines Market has witnessed significant developments, particularly in response to ongoing global health challenges. In October 2023, Pfizer and Moderna reported increased production capabilities for their mRNA vaccines, focused on addressing proposed booster shots for emerging variants. Merck and Co has intensified its Research and Development efforts in vaccine therapeutics, focusing on collaborations with biotech firms to expedite vaccine innovation. AstraZeneca's vaccine collaboration with various health entities has led to expanding distribution networks in underserved populations across the United States.

In terms of mergers and acquisitions, in August 2023, Novavax completed its acquisition of a biotechnological firm specializing in vaccine delivery systems to enhance its product pipeline. There have also been reports of increased valuations for companies such as GlaxoSmithKline and Johnson and Johnson, fueled by enhanced funding for vaccine accessibility and newer product developments aimed at combating infectious diseases. The market growth has been positively impacted by regulatory support from US health agencies, stimulating demand for diverse vaccine options, as the country remains vigilant against potential influenza surges and new viral threats.

Overall, these activities signify a dynamic phase in the US Human Vaccines Market.

## Report Scope

| MARKET SIZE 2024 | 151.52(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 160.02(USD Million) |
| MARKET SIZE 2035 | 276.25(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.61% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer (US), Moderna (US), AstraZeneca (GB), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), Novavax (US), Bharat Biotech (IN) |
| Segments Covered | Type, Application, Administration Route, Target Diseases |
| Key Market Opportunities | Advancements in mRNA technology enhance efficacy and speed of human vaccines development. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation and competition in the human vaccines market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US human vaccines market in 2024?**
A: The overall market valuation of the US human vaccines market was $151.52 Million in 2024.

**Q: What is the projected market valuation for the US human vaccines market by 2035?**
A: The projected market valuation for the US human vaccines market is $276.25 Million by 2035.

**Q: What is the expected CAGR for the US human vaccines market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US human vaccines market during the forecast period 2025 - 2035 is 5.61%.

**Q: Which companies are considered key players in the US human vaccines market?**
A: Key players in the US human vaccines market include Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., Novavax, and Bharat Biotech.

**Q: What are the market segments based on vaccine type in the US human vaccines market?**
A: The market segments based on vaccine type include Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid.

**Q: What was the valuation range for Inactivated vaccines in 2024?**
A: The valuation range for Inactivated vaccines in 2024 was between $30.0 Million and $55.0 Million.

**Q: What is the projected valuation for Preventive Vaccines by 2035?**
A: The projected valuation for Preventive Vaccines is expected to reach between $60.0 Million and $110.0 Million by 2035.

**Q: What are the different administration routes for vaccines in the US human vaccines market?**
A: The different administration routes for vaccines include Intramuscular, Subcutaneous, Oral, and Intradermal.

**Q: What was the valuation for Influenza Vaccines in 2024?**
A: The valuation for Influenza Vaccines in 2024 was between $41.52 Million and $76.25 Million.

**Q: Which target diseases are addressed by vaccines in the US human vaccines market?**
A: Vaccines in the US human vaccines market address target diseases such as Infectious Diseases, Oncological Diseases, and Autoimmune Diseases.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-human-vaccines-market-15633*